Patrys Limited (AU:PAB) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Patrys Limited is pivoting its focus to the development of PAT-DX3 after facing manufacturing challenges with its PAT-DX1 deoxymab antibody. The company sees potential in PAT-DX3 for treating diseases beyond cancer, particularly in the inflammation space, thanks to its unique properties and ability to cross the blood-brain barrier. This strategic shift aims to enhance long-term value for shareholders by targeting conditions with significant unmet medical needs.
For further insights into AU:PAB stock, check out TipRanks’ Stock Analysis page.